SOPHiA GENETICS SA (NASDAQ:SOPH) Beats Q2 2025 Earnings Estimates, Shares Jump in Pre-Market Trading

SOPHiA GENETICS SA (NASDAQ:SOPH) Surpasses Analyst Estimates in Q2 2025, Shares Rise in Pre-Market Trading

SOPHiA GENETICS SA reported its second-quarter 2025 earnings, delivering both revenue and earnings per share (EPS) figures that exceeded analyst expectations. The company’s performance has been met with a positive market reaction, as reflected in pre-market trading activity.

Key Financial Highlights

• Revenue: Reported at $18.32 million, surpassing the consensus estimate of $17.83 million, marking a beat of approximately 2.75%.
• EPS: Came in at $0.33, significantly outperforming the estimated loss of -$0.2346. This swing to profitability is a notable development for the company.
• Pre-Market Reaction: Shares rose ~5.45% in pre-market trading, indicating investor optimism following the earnings release.

Market Performance Context

The stock’s recent performance has been mixed:

• Last Week: Down -1.79%
• Last Two Weeks: Down -5.44%
• Last Month: Up +1.54%

The pre-market surge suggests that the earnings beat has outweighed recent bearish sentiment, at least in the short term.

Forward-Looking Estimates

Analysts currently project:

• Q3 2025 Revenue Estimate: $18.91 million
• Q3 2025 EPS Estimate: -$0.2193
• Full-Year 2025 Revenue Estimate: $75.68 million
• Full-Year 2025 EPS Estimate: -$0.9384

While the Q2 results were strong, the company will need to maintain momentum to meet or exceed these forward estimates.

Press Release Summary

The earnings announcement highlighted SOPHiA GENETICS’ position as a leader in data-driven medicine, emphasizing its cloud-native software platform, SOPHiA DDM™. The company did not provide explicit forward guidance in the press release, but the earnings beat and continued collaborations—such as the expanded partnership with AstraZeneca to improve breast cancer outcomes using AI—suggest ongoing business strength.

For a deeper dive into SOPHiA GENETICS’ earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any investment decisions.